瘙痒的发生机制-相关疾病和治疗(丁媛)

col2005;18:745-753.14StarovaA,AlyR.Thesafetyandefficacyofciclopiroxolamineforthetreatmentofseborrheicdermatitis.ExpertOpinDrugSaf2005;4:235-239.15SquireRA,GoodeK.Arandomised,single-blind,single-cen-terclinicaltrialtoevaluatecomparativeclinicalefficacyofsham-pooscontainingciclopiroxolamine(1.5%)andsalicylicacid(3%),orketoconazole(2%,Nizora1)forthetreatmentofdan-druffseborrhoeicdermatitis.JDermatolTreat2002;l3:5l-60.16AlyR,KatzHI,KempersSE,etal.Ciclopiroxgelforseborrheicdermatitisofthescalp.IntJDermato12003;42(Suppl1):19-22.17PierardFC,PierardGE.Adouble-blindplacebo-controlledstudyofketoconazole+desonidegelcombinationinthetreatmentoffacialseboribeicdemmtitis.Dermatology2002;204:344-347.18PierardFC,PierardGE,ArreseJE,eta1.Effectofketoeonazolel%and2%shampoosonseveredandruffandseborrhoeicdermati-tis:clinica1,squamometricandmycologicalassessments.Dermatol2001;202:171-176.19MayserP,ArgembeauxH,RippkeF.Thehairstrandtestanewmethodfortestingantifungaleffectsofantidandruffpreparations.JCosmetSci2003;54:263-270.20SeiY.Seboribeicdermatitis-clinicaldiagnosisandtherapeuticvalueofdiferentdrugs.NipponIshikinGakkaiZasshi2003;44:77-80.21PirkhammerD,SeeberA,HonigsmannH,etal.Narrow-bandultravioletB(ATL-01)phototherapyisaneffectiveandsafetreatmentoptionforpatientswithsevereseborrhoeicdermatitis.BrJDermatol2000;143:964-968.22LingMR.Topicaltacrolimusandpimecrolimus:futuredirections.SeminCutanMedSurg2001;20:268-274.23SauderDN.Mechanismofactionandemergingroleofimmunere-sponsemodifiertherapyindermatologicconditions.JCutanMedSurg2004;8Suppl3:3-12.(:2006-01-18)、丁　媛　综述　普雄明　审校　　　瘙痒是一种引起搔抓欲望的不愉快的主观感觉,由于缺乏合适的动物模型及实验方法,人们至今还不能全面认识瘙痒,本文就近年来对瘙痒的发生机制、相关疾病和治疗的进展作一综述,为临床诊断及治疗提供参考。　瘙痒　发生机制　疾病　治疗　　,,,、。1　1.1　,(),、、、、、、。,、、,,1。1.2　,C,,(),,(0.5ms)、、C,。CC:,,830000,,。1.3　　,,,,A,,2。,,,C,,,3。2　2.1　　,,,,H1、H2、H3。,:、、、,492ChinaJLeprSkinDis.Jun2006,Vol.22,No.64。2.2　　,(M1-M5),:,,。M25,-C。2.3　5-　5-,,,。2.4　　,,。2.5　P　(MC)P(SP),SP、、,SP,,SP,。SP,MCE2。2.6　(IL)　IL-2;IL-4,6。2.7　　、B-,(u、k、δ),,,,,u-,k-,SP,1。3　,,,。3.1　　,:(、)、、(、)、、、、、、、、。:10%,6,,,,,,、、,。:80%,,,,。,,,。:Ozdemir717820,2,16,2,96%。,5。3.2　　(),,、、,(60%～80%)8。,,,,(u-k-)。:,,9。:、、T、、、、,50%,30%。HIV:HIV,:、、、、、2。,,,,、10。:,、、、,、,,。:。,、、、,。:、。、、、493中国麻风皮肤病杂志　2006年6月第22卷第6期;、、、、。:,。4　4.1　4.1.1　　UVB11,UVB()、、。4.1.2　　Nilsson,27,,,,12。4.2　4.2.1　PH　,,PH,、、。4.2.2　　、、,,。4.2.3　　(EMLA),,。4.2.4　　H1,,,。4.2.5　　P、、、P,Lysy44(0.06%),30(65.2%)13。Stander33(0.025%～0.3%),3314。4.2.6　　,,,。4.2.7　　15,,,、、、,、。4.3　　,,。4.3.1　,Brune13350～150mg,(、、、)、、、,:86(65.4%),、、16。4.3.2　　5-,Zylicz,,26,17,4,5,20mg,7,2,2417。4.3.3　　Daly1118,、、、、,。4.3.4　　5-,19。4.3.5　,Davis、20,21。1StanderS,SteinhoffM,SchmelzM,etal.Neurophysiologyofpru-ritus:Cutaneouselicitationofitch.ArchDermatol2003;139:1463-1470.2YosipovitchG,GreavesMW,SchmelzM.Itch.Thelancet2003;361:690-695.3YosipovitchG,HundleyJ.Practicalguidelinesforreliefofitch.DermatologyNursing2004;16:325-328.4TwycrossR,GreavesMW,HandwerkerH,etal.Itch:scratchingmorethanthesurface.QJM2003;96:7-26.5WessJ,DuttaroyA,GomezaJ,eta1.Muscarinicreceptorsubtypesmediatingcentralandperipheralantinociceptionstudiedwithmusca-rinicreceptorknockoutmice:areview.LiteSci2003;72:2047-2054.6ChanLS,RobinsonN,XuL.Expressionofinterleukin-4intheepidermisoftransgenicmiceresultsinapruriticinflammatoryskindisease:anexperimentalanimalmodeltostudyatopicdermatitis.JInvestDermato12001;117:977-983.7OzdemirM,TuzunY.Herpeszosterandpruritus.InternationJour-nalofDermatology2004;43:779-780.494ChinaJLeprSkinDis.Jun2006,Vol.22,No.68LazrakS,SkaliH,BenchikhiH,eta1.Phototherapyandhemodi-alysispruritus.Nephrologie2004;25:293-295.9BergasaNV.Anapproachtothemanagementofthepruritusofchol-estasis.ClinLiverDis2004;8:55-66.10SinghF,RudikoffD.HIV-associatedpruritus:etiologyandman-agement.AmJClinDermato12003;4:177-188.11WallengrenJ,SundlerF.Phototherapyreducesthenumberofepi-dermalandCGRP-positivedermalnervefibres.ActaDermVene-reol2004;84:111-115.12NilssonHJ,PsouniE,CarstamR,etal.ProfoundinhibitionofchronicitchInducedbystimulationofthincutaneousnervefibres.JEurAcadDermato1Venereo12004;18:37-43.13JLysy,MSistiery-Ittah,YIsraelit,etal.Topicalcapsaicin-anovelandeffectivetreatmentforidiopathicintractablepruritusani:arandomised,placebocontrolled,crossoverstudy.Gut2003;52:1323-1326.14StanderS,LugerT,MetzeD.Treatmentofprurigonodulariswithtopicalcapsaicin.JAmAcadDermato12001;44:471-478.15StanderS,LugerTA.Antipruriticeffectsofpimecro1imusandtacro1imus.Hautarzt2003;54:413-417.16BruneA,MetzeD,LugerTA.AntipruritictherapywiththeoralopioidreceptorantagonistnaltrexoneOpen,non-placebocont-ro11edadministrationin133patients.Hautarzt2004;55:1130-1136.17ZyliczZ,KrajnikM,SorgeAA.Paroxetineinthetreatmentofse-verenon-dermatologicalpruritus:arandomized,controlledtrial.JPainSymptomManage2003;26:1105-1112.18DalyBM,ShusterS.Antipruriticactionofthalidomide.ActaDermVenereo12000;80:24-25.19SchumannR,HudcovaJ.Cholestasisofpregnancy,pruritusand5-hydroxytryptamine3receptorantagonists.ActaObstetGyneco1Scand2004;83:861-862.20DavisMP,FrandsenJL,WalshD,etal.Mirtazapineforpruritus.JPainSymptomManage2003;25:288-291